Intrathecal drug delivery dramatically reduces systemic opioid use in patients with advanced cancer, according to new research.
A major advantage of intrathecal dosing is that the medication goes directly where it’s needed, according to co-author Shane E. Brogan, MB BCh, an associate professor of anesthesia at the University of Utah and the director of pain medicine at the Huntsman Cancer Institute, in Salt Lake City. With oral opioids, “some of the medication gets to the spinal